Lord’s Mark Industries Ltd to Go Public on BSE, Eyes NSE Listing and Global Expansion

Mumbai (Maharashtra) [India], August 5: Lord’s Mark Industries Ltd, a prominent and rapidly growing Indian conglomerate with business interests spanning healthcare, diagnostics, renewable energy, and cutting-edge technology, is poised to make its mark on the capital markets with an upcoming listing on the Bombay Stock Exchange (BSE). This milestone move reflects the company’s strategic ambition to elevate its presence, not just within India, but across global business landscapes.

This listing follows the company’s recent National Company Law Tribunal (NCLT) clearance for the merger with Lord’s Mark India Ltd (formerly Kratos Energy and Infrastructure Ltd) — a significant development that is reshaping the group’s business trajectory. The merger is designed to unlock operational efficiencies, enabling greater resource optimisation, streamlined management, and robust expansion into new verticals.

Beneficial Share Swap for Investors

As part of the merger structure, shareholders of Lord’s Mark Industries Ltd will be entitled to a share swap ratio of 1:1.25. For every share held in Lord’s Mark Industries Ltd, investors will receive 1.25 shares in the newly consolidated Lord’s Mark India Ltd. This favourable ratio underscores the company’s commitment to creating value for its shareholders and supports the vision of building a stronger, more dynamic corporate entity.

Strong Global Investor Backing and Strategic Partnerships

The announcement of the BSE listing has also been accompanied by significant interest from international investors, demonstrating robust confidence in Lord’s Mark Industries’ diversified business approach, resilience, and forward-looking strategies. Notably, the company has received a high-value proposal for a global partnership concerning its Medtech product line—a flagship portfolio in the green energy segment. This partnership is poised to accelerate the company’s international reach and solidify its standing as a key player in the renewable energy market.

Capital Market Journey: BSE Launch, NSE on the Horizon

The BSE listing serves as the launchpad for Lord’s Mark Industries’ wider capital market journey. With eyes set on further growth, the company has initiated plans to pursue a listing on the National Stock Exchange (NSE) within the next six months. This dual-exchange presence is anticipated to boost stock liquidity, expand the investor base, and enhance visibility among both domestic and foreign institutional investors. The NSE listing will also offer better price discovery and increased access to capital—factors that are crucial for the company’s future growth plans.

To know more, visit: www.lordsmark.com

If you have any objection to this press release content, kindly contact [email protected] to notify us. We will respond and rectify the situation in the next 24 hours.

aayush jain acquisition Business cashew processing cote d’ivoire esos 2026 pacific global fzco Pajson Agro pulkit jain Royal Mewa Share Swap

From Local to Global: Pajson Agro India to Acquire Pacific Global FZCO, Adding 60,000 MT Capacity at the World’s Largest Cashew Origin

All-stock 100% acquisition | ₹354.52 crore | Board also approves ESOS 2026 New Delhi [India], November 6: Pajson Agro India Limited (PAJSON | 544657 | INE14LM01012), a vertically integrated cashew processing company with farm-gate sourcing across key producing origins and a growing consumer brand, ‘Royal Mewa’, has announced that its Board of Directors, has approved […]

Read More
Business Fredun Pharmaceuticals EBITDA Growth Fredun Pharmaceuticals H1 FY27 Results Fredun Pharmaceuticals Net Profit Fredun Pharmaceuticals Revenue Growth Indian pharmaceutical industry

Fredun Pharmaceuticals On A Growth Overdrive: Net Profit Soars 94%, Ebitda Rockets 92% And Revenue Surges 87% In H1 Fy27

Mumbai (Maharashtra) [India], November 6: Fredun Pharmaceuticals Limited (BSE – FREDUN | 539730), one of India’s leading pharmaceutical formulation manufacturing companies, has announced its unaudited financial results for Q2 & H1 FY27. The Company offers a diversified portfolio spanning generics, cosmeceuticals, nutraceuticals, mobility solutions, and animal healthcare products. Key Financial Highlights Standalone key Financial Highlights […]

Read More
Business

Patil Automation Marks a Strong First Half of FY27; Consolidated Revenue Up 37% YoY, Net Profit Up 48%

Mumbai (Maharashtra) [India], November 6: Patil Automation Limited (NSE: PATILAUTOM | INE17GV01016), a leading provider of turnkey welding, assembly and robotics-integrated automation solutions, has released its Unaudited Standalone and Consolidated Financial Results for the half year ended September 30, 2026, reporting broad-based growth across the group. Performance Snapshot – H1 FY27 H1 FY27 Key Financial […]

Read More